PSTI Stock Forecast: 20.79% Gain In 7 Days


Pluristem Therapeutics, Inc. (PSTI) was a top stock pick based on predictive algorithm recommended to I Know First subscribers on January 21st for the 7-day time horizon. Pluristem Therapeutics had a signal of 25.26 and a predictability of 0.23. In accordance with the algorithm, the company reported short-term capital gains of 20.79%.

PSTI was part of the stock forecast that can be found in the “Small Cap” Package.

The full Top 10 Small Cap Stocks forecast includes a daily prediction for a total of 20 stocks with bullish and bearish signals:

  • Top ten stocks picks to long
  • Top ten stocks picks to short

Pluristem Therapeutics Inc., through its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. The company focuses on the research, development, clinical trial, and manufacture of cell therapeutics products and related technologies for the treatment of various ischemic and inflammatory conditions.

The upward movement observed with Pluristem stock price has been attributed to a bullish report from Acceleron equity research. Acceleron itself is a stock market research firm focused on emerging companies and technologies.

The same report estimates EPS of $0.40 in 2017 and $1.25 in 2018. As can be read on the report, Acceleron believes the company will make significant progress this year in its clinical pipeline. Also, new Adaptive Licensing legislation in the European Union allows for limited commercialization of cell therapies after a successful Phase 2 study. Pluristem has yet to disclose a timeline for approval, however.

This recent positive trend, in which the stock went from $2.80 to around $3.40, goes along with the bullish I Know First forecast for the company, sent to it’s subscribers on January 21st, on the Small Cap Package, which had a positive signal of 25.26.